
Enhancing Awareness and Participation of Black Breast Cancer Patients in Clinical Trials
Coral Omene, MD, PhD, medical oncologist in the Stacy Goldstein Breast Cancer Center at Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center together with RWJBarnabas Health, has been awarded a $50,000 grant from the V Foundation for Cancer Research in partnership with ESPN to increase clinical trial awareness and enrollment of Black women with breast cancer.
According to the American Cancer Society, breast cancer is the most commonly diagnosed cancer among Black women, with an estimated 36,260 new cases expected to be diagnosed in 2022. While there has been an overall decline in breast cancer deaths over the last 30 years, there is a persistent and significant mortality gap between Black women and White women. These differences are multifactorial but are in part a result of underrepresentation of Black patients in clinical trials, which provide the highest level of evidence in evaluating the safety and efficacy of new cancer treatments.
“Clinical trials, which are a vital step in bringing new cancer therapies to patients, have strikingly low rates of Black female participants, which is a critical, unaddressed public health concern and an important target for intervention,” notes Dr. Omene, who is also a member of the
“Addressing disparities in cancer care, including access to and participation in clinical trials, has long been a priority for Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health,” says
The efforts in this funded proposal to increase clinical trial participation among Black breast cancer patients will include tailored patient education; advocacy and outreach; patient navigation; and physician engagement and outreach. Importantly, notes Dr. Omene, this project will serve as a guide for increasing clinical trial participation among Black patients with other cancers that disproportionately affect this population, including colorectal, lung and prostate cancers.
The project period runs through June 2023.



































